SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 196.08-0.2%Jan 15 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (10440)10/30/1997 5:27:00 PM
From: Pseudo Biologist  Read Replies (2) of 32384
 
[off-topic Xoma/Seragen]

Henry, Andy, Xoma used to be a hotbed for immunotoxins: antibody fragments fused to protein toxins such as ricin A chain. I think they still have some of those programs going, although, clinically at the moment, they are primarily focused on BPI and related molecules (as Andy very well knows).

Seragen's molecules may be thought as similar to immunotoxins: take an anti-IL-2-receptor or anti-EGF-receptor Ab fragment and you'd get, in principle, very similar molecules, functionally, to what SRGN (or is it Lilly?) has.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News